预约演示

更新于：2025-05-07

Moxifloxacin Hydrochloride

盐酸莫西沙星

更新于：2025-05-07

概要

基本信息

药物类型

小分子化药

别名

MFLX、Moxifloxacin、Moxifloxacin Hydrochloride and Sodium Chloride

+ [25]

靶点

Bacterial DNA gyrase x Bacterial top IV

作用方式

抑制剂

作用机制

Bacterial DNA gyrase 抑制剂(细菌DNA旋转酶抑制剂)、Bacterial top IV抑制剂(细菌拓扑异构酶IV抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Fresenius Kabi USA LLC

Bayer AG

Arrotex Pharmaceuticals Pty Ltd.

+ [7]

非在研机构

Bayer HealthCare AG

拜耳医药保健有限公司

Bayer HealthCare Pharmaceuticals, Inc.

+ [4]

权益机构

Harrow, Inc.

Novartis AG

最高研发阶段批准上市

首次获批日期

美国 (1999-12-10),

急性细菌性鼻窦炎慢性支气管炎社区获得性肺炎

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C21H24FN3O4

InChIKeyFABPRXSRWADJSP-MEDUHNTESA-N

CAS号151096-09-2

查看全部结构式(2)

关联

414

项与盐酸莫西沙星相关的临床试验

NCT06441006

/ Not yet recruiting临床3期IIT

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PRISM-TB)

PRISM-TB is an international, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, noninferiority Phase 3 clinical trial for fluoroquinolone-susceptible multidrug-resistant/rifampin-resistant pulmonary tuberculosis (FQ-S MDR/RR-TB).
The trial objective is to evaluate whether stratified medicine treatment strategies for FQ-S MDR/RR-TB, defined by a pre-specified risk stratification algorithm, have noninferior efficacy to a one-size-fits-all control regimen (the local standard-of-care [SOC] regimen consistent with preferred regimen(s) in international guidelines), as measured by TB-related unfavorable outcomes at Week 73.

开始日期2026-10-01

申办/合作机构

The University of California, San Francisco

[+1]

NCT03244072

/ Not yet recruiting临床2/3期

Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

开始日期2025-06-01

申办/合作机构

Zion Therapeutics, LLC

NCT06917495

/ Not yet recruiting临床2期IIT

Rifapentine- And Moxifloxacin-Containing Short-Course Regimens for Mild Spinal Tuberculosis: A Multicenter, Randomized, Non-inferiority Clinical Trial

To evaluate the non-inferiority in efficacy between the rifapentine- and moxifloxacin-containing short-course regimens (with rifampicin replaced by rifapentine and ethambutol replaced by moxifloxacin, while isoniazid and pyrazinamide remaining the same as the empirical regimen) and the empirical long-course regimen, so as to determine whether it is possible to shorten the treatment duration to 26 weeks for patients with mild spinal tuberculosis.

开始日期2025-04-05

申办/合作机构

山东大学

[+1]

100 项与盐酸莫西沙星相关的临床结果

登录后查看更多信息

100 项与盐酸莫西沙星相关的转化医学

登录后查看更多信息

100 项与盐酸莫西沙星相关的专利（医药）

登录后查看更多信息

12,849

项与盐酸莫西沙星相关的文献（医药）

2025-12-31·Gut Microbes

A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity

Article

作者: Guedj, Jeremie ; Burdet, Charles ; Corbel, Tanguy ; Ferreira, Stéphanie ; de Gunzburg, Jean ; Olivares, Carlos ; Ruppé, Etienne ; Andremont, Antoine

Metagenomic sequencing deepened our knowledge about the role of the intestinal microbiota in human health, and several studies with various methodologies explored its dynamics during antibiotic treatments. We compared the impact of four widely used antibiotics on the gut bacterial diversity. We used plasma and fecal samples collected during and after treatment from healthy volunteers assigned to a 5-day treatment either by ceftriaxone (1 g every 24 h through IV route), ceftazidime/avibactam (2 g/500 mg every 8 h through IV route), piperacillin/tazobactam (1 g/500 mg every 8 h through IV route) or moxifloxacin (400 mg every 24 h through oral route). Antibiotic concentrations were measured in plasma and feces, and bacterial diversity was assessed by the Shannon index from 16S rRNA gene profiling. The relationship between the evolutions of antibiotic fecal exposure and bacterial diversity was modeled using non-linear mixed effects models. We compared the impact of antibiotics on gut microbiota diversity by simulation, using various reconstructed pharmacodynamic indices. Piperacillin/tazobactam was characterized by the highest impact in terms of intensity of perturbation (maximal [IQR] loss of diversity of 27.3% [1.9; 40.0]), while moxifloxacin had the longest duration of perturbation, with a time to return to 95% of baseline value after the last administration of 13.2 d [8.3; 19.1]. Overall, moxifloxacin exhibited the highest global impact, followed by piperacillin/tazobactam, ceftazidime/avibactam and ceftriaxone. Their AUC between day 0 and day 42 of the change of diversity indices from day 0 were, respectively, -13.2 Shannon unit.day [-20.4; -7.9], -10.9 Shannon unit.day [-20.4; -0.6] and -10.1 Shannon unit.day [-18.3; -4.6]. We conclude that antibiotics alter the intestinal diversity to varying degrees, both within and between antibiotics families. Such studies are needed to help antibiotic stewardship in using the antibiotics with the lowest impact on the intestinal microbiota.

2025-07-01·Materials Science in Semiconductor Processing

Polydopamine-mediated interfacial optimization in WO3/@PDA/Ag3PO4 heterojunction for enhanced photocatalytic degradation of organic pollutants

作者: Deng, Biao ; Zhang, Mengmeng ; Zhu, Rongxiang ; Huang, Yi

To increase active sites, mitigate photo corrosion, expedite electron transfer and suppress the recombination of photogenerated charge carriers, we synthesized a WO₃@PDA/Ag₃PO₄ ternary composites using a straightforward method, where PDA served as adhesion interface and electronic transfer bridge.The photocatalytic activity of WO₃@PDA/Ag₃PO₄ was assessed by degrading organic pollutants under visible light.The results demonstrated that 0.5 g/L WO₃@PDA/Ag₃PO₄ could eliminate ₃₀ mg/L of methyl orange (MO) within ₆₀ min and achieve an _80.7 % degradation rate for moxifloxacin (Mox) within ₁₈₀ min.After five adsorption-photocatalytic cycles, the WO₃@PDA/Ag₃PO₄ maintained a removal efficiency of 95.88% for MO and 75.56% for Mox, showcasing its cycling stability.The photocatalytic mechanism of WO₃@PDA/Ag₃PO₄ was elucidated through a series of characterizations, which indicated that the Z-type heterojunction formed between WO₃ and Ag₃PO₄, along with PDA's electron-conducting ability, provided a strong driving force for the photocatalytic reaction.This study introduces an idea for enhancing the construction of Z-type heterojunctions with PDA as the electron-conducting interface, thereby improving photocatalytic performance.

2025-07-01·Materials Chemistry and Physics

Moxifloxacin-loaded Co0.9Zn0.1Fe1.975Dy0.025O4 magnetic nanoparticles coated with alginate and chitosan: Investigating drug release and antibacterial properties

作者: Ramezani, Vahid ; Seifoddini, Amir ; Hasani, Saeed ; Rakhsha, Leila ; Khajehkhalili, Mahdiyeh

Biopolymer-coated magnetic nanoparticles (MNPs) present a promising avenue for biomedical applications due to their exceptional properties.In this study, Co_0.9Zn_0.1Fe_1.975Dy_0.025O₄ ferrite nanoparticles were synthesized using the co-precipitation method and characterized.The average crystallite size of the MNPs was determined as 38.89 nm.Two distinct systems were created by coating the MNPs with alginate and chitosan, followed by loading them with moxifloxacin.Various anal. techniques confirmed the saturation magnetization values of the MNPs and coated MNPs, as well as the drug loading percentages.The hydrodynamic sizes of the coated MNPs were reported as 401.1 nm for alginate and 192.2 nm for chitosan.UV-Vis spectroscopy was used to determine the amount of moxifloxacin loaded onto the nanoparticles, revealing that the drug loading was 19.64 % for the alginate-coated MNPs and 21.85 % for the chitosan-coated MNPs.An in vitro drug release study unveiled the impact of pH and coating polymer on the release kinetics, with significantly different release rates observed between the two pH conditions.The results indicated that at pH 7.4, the percentage of drug released in 6 h was 97.89 % for the alginate-coated MNPs and 70.36 % for the chitosan-coated MNPs.Conversely, at pH 5.5, the drug release percentages were 48.6 % for the alginate-coated MNPs and 73.33 % for the chitosan-coated MNPs.Moreover, the antibacterial activity of the MNPs against gram-pos. and gram-neg. bacteria was investigated, demonstrating the enhanced antibacterial efficacy conferred by the alginate and chitosan coatings.This comprehensive anal. underscores the potential of biopolymer-coated MNPs as effective drug delivery systems with tailored release profiles and enhanced antibacterial properties.

291

项与盐酸莫西沙星相关的新闻（医药）

2025-04-28

·DrugAI

Nat. Commun. | 利用群体关联建模增强对多重耐药微生物的诊断

DRUGAI今天为大家介绍的是来自美国杜兰大学医学院的Tony Ye Hu与Wenshu Zheng团队发表的一篇论文。科研人员开发出一种新的群体关联模型（Group Association Model, GAM），用于发现细菌对抗生素产生抗药性的遗传变异特征。这个模型不需要依赖已有的专业知识库，就能准确找出与耐药性相关的基因变异，同时还能减少错误判断细菌对多种药物同时产生抗性的情况。研究团队用这个模型分析了超过7000株结核分枝杆菌（Mycobacterium tuberculosis, Mtb）样本。结果显示，与世界卫生组织（WHO）现有的基于专家经验的突变检测方法相比，GAM在识别各类药物的目标基因时表现相当，但更少出现误判。为了证明模型的通用性，研究人员还分析了近4000株金黄色葡萄球菌（S. aureus）样本，同样取得了很高的预测准确率。通过引入机器学习（ML）技术对GAM进行优化，模型在处理小规模或不完整数据时的预测能力得到进一步提升。研究团队在三个不同地点收集的427个结核分枝杆菌样本中验证了这一发现，结果表明GAM提供的数据比WHO的方法更适合用于机器学习预测。这种结合了GAM和机器学习的新方法有望突破现有耐药性预测技术的限制，为耐药性细菌感染的治疗方案选择提供更好的指导。微生物耐药性已成为一个日益严重的全球健康问题。这种耐药性主要源于基因突变、基因横向转移以及抗生素的过度使用。最新研究显示，2021年全球新增了超过1000万例结核病病例，其中约160万人不幸死亡。特别值得注意的是，有45万例患者对常用的抗结核药物利福平产生了耐药性。虽然结核病的整体治疗成功率达到86%，但对于出现耐药性的病例，治愈率仅为57%。为了应对这一挑战，研究人员开发出一种新的群体关联模型（GAM）。这个模型通过分析7179个结核分枝杆菌样本，成功识别出8种主要抗结核药物各自对应的特定耐药基因，避免了传统基因组关联研究（GWAS）方法容易出现的错误关联。研究团队还用近4000个金黄色葡萄球菌样本验证了该模型的普适性。图 1传统的耐药性检测方法存在明显缺陷：培养法不仅耗时费力，对于生长缓慢的细菌可能需要数周时间；分子检测方法虽然较快，但只能识别已知的常见突变；DNA测序虽然能发现新的突变，但准确判断这些突变是否导致耐药性仍然困难。研究发现，将GAM与机器学习技术相结合（如图1所示）能显著提升预测准确性，特别是在处理小规模或不完整数据时表现更为出色。这一发现为临床上快速识别耐药性细菌，制定更有效的治疗方案提供了新的可能。耐药分离株的群体特征图 2研究团队对超过1.2万个结核分枝杆菌基因组数据进行了全面分析。为确保研究质量，研究人员首先进行了严格的数据筛选，最终保留了约1万个高质量样本（DS1），其中包括7179个完整的耐药性数据样本（DS2）。通过系统发育分析（如图2a, b所示），研究人员发现这些样本在结核分枝杆菌的四个主要家族中分布均匀，这说明研究结果不会因为样本选择偏差而失真。为了更好地研究耐药性特征，研究团队创新性地将样本按照它们对不同药物的耐药模式进行分组，形成了126个研究组（如图2c所示）。分析结果显示，在所有样本中，超过一半（54.7%）对13种受试药物都保持敏感。在耐药样本中，绝大多数（86.6%）属于较大规模的组别（每组至少14个样本）。研究还发现不同类型药物的耐药情况差异显著：一线用药中，异烟肼的耐药率最高，达到74%；其次是利福平，为67%；乙胺丁醇约为49%；二线替代药物利福布汀的耐药率也达到62%，其他二线药物的耐药率在24-42%之间；新型药物和重新启用的老药耐药率最低，仅为6-23%。这种分组分析方法不仅帮助研究人员更准确地识别药物与基因之间的关联，也为了解不同药物的耐药发展趋势提供了重要参考。与耐药表型相关的基因和突变的鉴定图 3研究团队开发的GAM方法在识别耐药性相关基因变异方面取得了重要突破。如图3所示，这种新方法能够准确找出6个与主要抗结核药物相关的关键基因，且几乎不会出现误判，仅在异烟肼相关基因katG与利福平的关联中出现了一次误报。与传统的基因组关联分析方法（GWAS线性混合模型）相比，GAM的优势非常明显：准确性大幅提升：传统方法在识别每种药物的目标基因时，往往会产生数千个错误关联，而GAM最多只有1-2个误判；预测效能显著提高：GAM的阳性预测准确率是传统方法的200多倍；抗干扰能力强：即使在不同耐药性之间存在重叠的情况下，GAM也能准确区分各种药物的特定耐药基因。为了验证GAM的通用性，研究人员还分析了近4000个金黄色葡萄球菌样本。结果表明，GAM不仅能识别出由基因突变引起的耐药性（如环丙沙星等3种药物），还能发现通过基因在细菌之间传递而产生的耐药性（如庆大霉素等4种药物）。这些发现对临床治疗具有重要意义：GAM能够帮助医生更准确地预测病原体对不同抗生素的耐药性，从而制定更有效的治疗方案，减少抗生素的滥用，延缓耐药性的发展。图 4如图4所示，研究团队比较了GAM、WHO目录和GAM+机器学习三种方法的预测性能。GAM与WHO的2021和2023年结核分枝杆菌突变目录的重叠率为1.2-80.0%。在9种机器学习模型中，梯度提升法表现最佳，平均准确率达81.0%，方差最低（1.66%）。GAM+机器学习组合在预测利福平耐药性时，特异性提高了10.9%。对于阿米卡星、乙硫异烟胺、异烟肼、卡那霉素和左氧氟沙星等药物的敏感性也有所提升。接收者操作特征曲线（AUC）值达到85.0-97.0%，优化后的模型整体准确率提高了2.6%。图 5在图5中，研究团队评估了样本量和数据完整性对GAM性能的影响。在179-7179个样本的测试中，GAM与样本量呈渐近关系，在中点处出现拐点。虽然LMM识别出的真阳性略多，但其假阳性率是GAM的100-1000倍。数据缺失率与基因识别准确性呈反S形关系。通过机器学习优化后，即使只用1%的数据作为训练集，预测准确率也能达到0.767，接近使用75%数据的模型（0.801）。这说明机器学习能够有效缓解数据缺失对GAM分析的影响，但GAM的基因检测仍然依赖于样本量。图 6随后，研究团队比较了GAM和WHO目录在机器学习预测中的表现（图6）。使用梯度提升机器学习模型测试发现，GAM在预测阿米卡星、异烟肼、卡那霉素和利福平的耐药性时，准确率高于WHO模型。在427个来自中国三家医院的结核分枝杆菌样本验证中，GAM+机器学习模型在预测6种药物（乙胺丁醇、乙硫异烟胺、异烟肼、卡那霉素、莫西沙星和利福平）的耐药性时表现更优，在其他药物上的预测效果持平。讨论研究团队开发的GAM方法在分析复杂耐药谱的微生物群体时展现出独特优势。与传统方法相比，GAM不依赖已知的耐药机制知识，能自动过滤中性突变，减少假阳性和交叉耐药性的干扰。特别是当与机器学习技术结合后，GAM在处理完整数据和不完整数据时都表现出色，为预测药物-基因关联提供了更准确的工具。虽然GAM在识别水平基因转移等某些耐药机制方面还有局限，但其在多种病原体（如结核分枝杆菌、金黄色葡萄球菌等）的耐药性分析中都展现出良好应用前景。这一方法不仅可用于指导临床用药，还可能帮助作物育种等其他领域的抗性研究。编译|于洲审稿|王梓旭参考资料Saliba J G, Zheng W, Shu Q, et al. Enhanced diagnosis of multi-drug-resistant microbes using group association modeling and machine learning[J]. Nature Communications, 2025, 16（1）: 2933.

微生物疗法放射疗法

2025-04-24

·PRNewswire

Price of Key DR-TB Medicine Drops 25% as TB Alliance's Multi-Manufacturer Strategy Expands Access

TB Alliance's third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving affordability and access NEW YORK, April 24, 2025 /PRNewswire/ -- TB Alliance applauds a new milestone in the fight against drug-resistant tuberculosis (DR-TB): a 25% price reduction for pretomanid, a key component of the BPaL/M regimens. Pretomanid is now available through the Global Drug Facility (GDF) at just $169 per treatment course—less than $1 per day, a key pricing benchmark identified by the global TB advocacy community. This latest price drop—down from $364 upon pretomanid's initial approval in 2019, and down further from $224 in October 2024—reflects ongoing efforts by TB Alliance and its partners to broaden access and improve affordability through a multi-manufacturer approach to access. TB Alliance, a nonprofit organization that developed pretomanid, has pioneered an innovative access model by partnering with multiple quality-assured manufacturers. This strategy helped launch pretomanid at an initial low price and ensured rapid, sustainable, and affordable access across high-TB burden countries. Simultaneously, by enabling healthy competition and fostering multiple high-quality supply sources, TB Alliance's strategy expanded availability while driving down costs. "This progress demonstrates how thoughtful collaboration and planning can translate into real-world impact," said Dr. Mel Spigelman, President and CEO of TB Alliance. "By enabling multiple high-quality producers to supply this medicine, we're fostering a healthy and sustainable market to deliver on our mandate that the life-saving medicines we develop will be adopted, available, and affordable to all those in need. We're grateful to partners such as Lupin and GDF for their shared commitment to supplying the market with life-saving TB medicines and stand committed to working with all our manufacturing partners to ensure equitable and affordable access." The current GDF price reduction, led by Lupin Limited, represents a crucial step in delivering on this vision. Procurement through GDF will save an estimated $37 million annually according to The Stop TB Partnership, the organization responsible for managing GDF, allowing for the treatment of an additional 120,000 people with DR-TB. Together with recent price reductions for the other regimen components, the cost of a full BPaL/M treatment course has dropped to a new low of $310—less than $2 per day, and a 47% reduction from its December 2022 price. BPaL/M is a six-month treatment recommended by the World Health Organization to treat most forms of DR-TB. It consists of bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M). In 2024 alone, approximately 110,000 courses of pretomanid were ordered across the world—enough to treat more than 60% of the global market for DR-TB treatment, perhaps the fastest ever scale up for a new TB medicine in modern times. "Lupin is proud to collaborate with TB Alliance and the Global Drug Facility to make pretomanid, an essential medicine in the fight against multidrug-resistant TB, more accessible and affordable for TB patients across the globe," said Ramesh Swaminathan, Global CFO, Executive Director, Head of API Plus SBU at Lupin. "The recent price reduction reflects our strong and deep-rooted commitment to delivering high-quality and affordable medicines to TB patients worldwide. Through this partnership, we reaffirm our dedication to patient-centric innovation and equitable access, ensuring that countries burdened by TB have the necessary treatment options they need to save lives and strengthen public health systems." "For years, advocates from the TB community have called for TB treatments that are not just effective, but also affordable for every person who needs them," said Olya Klymenko, Development Director of TBPeopleUkraine. "The full BPaL/M regimen now costing less than $2 per day is deeply meaningful. We express our gratitude to everyone who made this result possible. There really is no reason for governments and health systems around the world to not provide these treatments to every person who can benefit from them." TB Alliance remains committed to expanding its innovative access model to ensure new innovations in TB treatment reach all who need them as rapidly as possible. With additional planned future tenders, TB Alliance expects additional price reductions for pretomanid in the future. Beyond pricing strategies, TB Alliance continues to develop and execute innovative market access initiatives like LIFT-TB, SLASH-TB, and the PeerLINC Knowledge Hub to speed the global uptake, procurement, and implementation of shortened DR-TB treatments for all who need them around the world. About TB TB is a difficult infection to cure, requiring patients to take a combination of medicines for at least four to six months. Even after symptoms disappear, medicines still need to be taken so that all traces of the disease can be fully eradicated. The scope and intensity of TB globally is in large part fueled by antiquated and inadequate TB drugs. Novel drug regimens are urgently needed to bring the TB pandemic under control. About BPaL The BPaL regimen—which combines the antibiotics bedaquiline (B), pretomanid (Pa), and linezolid (L)—was first clinically studied by TB Alliance. Pretomanid, as part of the BPaL regimen, received its first regulatory approval in August 2019 for use against highly drug-resistant strains of TB. Previously, less than two-thirds of drug-resistant TB patients around the world had been successfully treated. Treatment options were limited, expensive, toxic, and lengthy – requiring patients to take more than 20 pills per day for 9-20 months. About TB Alliance TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia's Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Foreign, Commonwealth and Development Office (United Kingdom), Cystic Fibrosis Foundation, Germany's Federal Ministry of Education and Research through KfW, Global Disease Eradication Fund (South Korea), Global Health Innovative Technology Fund, Irish Aid, Korea International Cooperation Agency, National Institute of Allergy and Infectious Diseases, South Korea's Ministry of Foreign Affairs, Unitaid, and the United States Agency for International Development. For more information, please visit: . Media Contact: Jess Wiggs at [email protected] SOURCE TB Alliance WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2025-04-13

·信狐药迅

天士力引进重磅孤儿药PXT3003治疗1A型腓骨肌萎缩症提交上市申请|新受理（4.7-4.13）

本周药品注册受理数据，分门别类呈现，一目了然。(4.7-4.13）新药上市申请药品名称企业注册分类受理号PXT3003江苏天士力帝益药业有限公司2.3CXHS2500027冻干人用狂犬病疫苗(无血清Vero细胞)艾美荣誉(宁波)生物制药有限公司2.2CXSS2500044新药临床申请药品名称企业注册分类受理号抗菌肽PL-3301口腔凝胶江苏普莱医药生物技术有限公司1CXHL2500381抗菌肽PL-3301口腔凝胶江苏普莱医药生物技术有限公司1CXHL2500380HRS-8829注射用浓溶液北京盛迪医药有限公司1CXHL2500379艾本那肽注射液常山凯捷健生物药物研发(河北)有限公司1CXHL2500378HRS-9821吸入粉雾剂广东恒瑞医药有限公司1CXHL2500377注射用TFX05-01浙江扬厉医药技术有限公司1CXHL2500373注射用SBK009成都施贝康生物医药科技有限公司1CXHL2500372VS-2218固体分散体片唯久生物技术(苏州)有限公司1CXHL2500369VS-2218固体分散体片唯久生物技术(苏州)有限公司1CXHL2500368DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500376DZD6008片迪哲(江苏)医药股份有限公司1CXHL2500375TQH3906胶囊正大天晴药业集团南京顺欣制药有限公司1CXHL2500371TQH3906胶囊正大天晴药业集团南京顺欣制药有限公司1CXHL2500370WEYZ-1乳膏南京韦尔优众医药有限公司1CXHL2500365DAT-1604片北京丹擎医药科技有限公司1CXHL2500364DAT-1604片北京丹擎医药科技有限公司1CXHL2500363XLH01片山东润中药业有限公司1CXHL2500367XLH01片山东润中药业有限公司1CXHL2500366IGP-14068-TM片杭州英创医药科技有限公司1CXHL2500361IGP-14068-TM片杭州英创医药科技有限公司1CXHL2500360177Lu-NRT6020注射液成都纽瑞特医疗科技股份有限公司1CXHL250035968Ga-NRT6020注射液成都纽瑞特医疗科技股份有限公司1CXHL2500358JMHT05湖南九典制药股份有限公司2.1;2.2CXHL2500357JMHT05湖南九典制药股份有限公司2.1;2.2CXHL2500356LN2222山东新时代药业有限公司2.2CXHL2500384LN2222山东新时代药业有限公司2.2CXHL2500383BCM957上海云晟研新生物科技有限公司2.2CXHL2500362盐酸羟钴胺注射液石药集团中奇制药技术(石家庄)有限公司2.4CXHL2500382舒沃替尼片迪哲(江苏)医药股份有限公司2.4CXHL2500374重组带状疱疹疫苗(CHO细胞)安徽智飞龙科马生物制药有限公司1.3CXSL2500282四价肠道病毒灭活疫苗(Vero细胞)国药中生生物技术研究院有限公司1.4CXSL2500283注射用RGL-232上海瑞宏迪医药有限公司1CXSL2500295CRG-B191注射液上海科锐克医药科技有限公司1CXSL2500293XKH001注射液浙江鑫康合生物医药科技有限公司1CXSL2500292XKH001注射液浙江鑫康合生物医药科技有限公司1CXSL2500291PM1300注射用冻干制剂珠海普米斯生物科技有限公司1CXSL2500290QX029N注射液江苏荃信生物医药股份有限公司1CXSL2500288注射用HY0001a四川汇宇海玥医药科技有限公司1CXSL2500294LNF2102注射液山东新时代药业有限公司1CXSL2500287SCG101-V自体T细胞注射液星源德生物医药(上海)有限公司1CXSL2500286注射用QLS32015齐鲁制药有限公司1CXSL2500285MSLN-CAR-T细胞注射液上海怡豪生物科技有限公司1CXSL2500281舒欣瑞纳注射液江苏贵琼药业有限公司1CXSL2500280KM1溶瘤痘苗病毒注射液深圳市华药康明生物药业有限责任公司1CXSL2500274KSD-101注射液中山恒赛生物科技有限公司1CXSL2500273注射用LY4101174礼来苏州制药有限公司1CXSL2500272JD012-CEL注射液北京景达生物科技有限公司1CXSL2500276注射用ZG006苏州泽璟生物制药股份有限公司1CXSL2500279注射用ZG005苏州泽璟生物制药股份有限公司1CXSL2500278注射用SKB315四川科伦博泰生物医药股份有限公司1CXSL2500270注射用SSGJ-612沈阳三生制药有限责任公司1CXSL2500269SSGJ-707注射液沈阳三生制药有限责任公司1CXSL2500268CM512注射液康诺亚生物医药科技(成都)有限公司1CXSL2500275重组抗IL-1β人源化单克隆抗体注射液三生国健药业(上海)股份有限公司1CXSL2500267注射用TQB6411正大天晴药业集团南京顺欣制药有限公司1CXSL2500266QL2109注射液齐鲁制药有限公司2.2CXSL2500284塔戈利单抗注射液四川科伦博泰生物医药股份有限公司2.2CXSL2500271仿制药申请药品名称企业注册分类受理号多种维生素注射液(13)辽宁海思科制药有限公司3CYHS2501413硫代硫酸钠注射液湖北成健药业有限公司3CYHS2501410注射用乳糖酸红霉素海南倍特药业有限公司3CYHS2501408二硫化硒洗剂江苏迪赛诺制药有限公司3CYHS2501404乙酰半胱氨酸片广州仁恒医药科技股份有限公司3CYHS2501401复方聚乙二醇(3350)电解质散合肥源丰顺医药科技有限公司3CYHS2501398聚乙二醇4000散成都恒瑞制药有限公司3CYHS2501395吡拉西坦注射液亚邦医药股份有限公司3CYHS2501394维生素K1注射液海南全盈药业有限公司3CYHS2501407盐酸美金刚口服溶液重庆赛诺生物药业股份有限公司3CYHS2501406布美他尼注射液合肥源丰顺医药科技有限公司3CYHS2501389盐酸多巴胺注射液广东南国药业有限公司3CYHS2501384盐酸多巴胺注射液广东南国药业有限公司3CYHS2501383琥珀酸亚铁片浙江赛默制药有限公司3CYHS2501379塞来昔布片昆明源瑞制药有限公司3CYHS2501388米诺膦酸片安徽博诺美科生物医药有限公司3CYHS2501386磷苯妥英钠注射用浓溶液南京正大天晴制药有限公司3CYHS2501342磷苯妥英钠注射用浓溶液南京正大天晴制药有限公司3CYHS2501341盐酸多巴胺注射液山东达冠医药科技有限公司3CYHS2501357盐酸多巴胺注射液山东达冠医药科技有限公司3CYHS2501355碳酸氢钠血滤置换液(无钾、无钙、0.6mmol/L镁)成都青山利康药业股份有限公司3CYHS2501352碳酸氢钠血滤置换液(钾2mmol/L 无钙)成都青山利康药业股份有限公司3CYHS2501350黄体酮注射液(Ⅱ)广州白云山明兴制药有限公司3CYHS2501363卢立康唑乳膏广东华润顺峰药业有限公司3CYHS2501361氯化钙注射液信合援生制药股份有限公司3CYHS2501356碳酸氢钠血滤置换液成都青山利康药业股份有限公司3CYHS2501351复方聚乙二醇(3350)电解质散西藏奥斯必秀医药有限公司3CYHS2501336磷酸奥司他韦颗粒广东瑞兴医药股份有限公司3CYHS2501318乳酸钠林格冲洗液上海长征富民金山制药有限公司3CYHS2501332伏格列波糖口腔崩解片山东朗诺制药有限公司3CYHS2501331盐酸曲唑酮片安徽省先锋制药有限公司3CYHS2501328苯磺酸氨氯地平口服溶液山东则正医药技术有限公司3CYHS2501327注射用苯唑西林钠成都晶富医药科技有限公司3CYHS2501324注射用苯唑西林钠成都晶富医药科技有限公司3CYHS2501323注射用苯唑西林钠成都晶富医药科技有限公司3CYHS2501322帕拉米韦注射液广州一品红制药有限公司3CYHS2501319西格列汀二甲双胍缓释片石药集团欧意药业有限公司3CYHS2501354西格列汀二甲双胍缓释片石药集团欧意药业有限公司3CYHS2501353阿昔洛韦钠注射液山东达冠医药科技有限公司3CYHS2501313阿昔洛韦钠注射液山东达冠医药科技有限公司3CYHS2501312维生素K滴剂重庆万霖生物医药科技有限公司3CYHS2501309艾拉莫德片南京臣功制药股份有限公司4CYHS2501420依折麦布片南京海鲸药业股份有限公司4CYHS2501419氟比洛芬凝胶贴膏河南羚锐制药股份有限公司4CYHS2501418沙库巴曲缬沙坦钠片山东鲁抗医药集团赛特有限责任公司4CYHS2501417沙库巴曲缬沙坦钠片山东鲁抗医药集团赛特有限责任公司4CYHS2501416沙库巴曲缬沙坦钠片山东鲁抗医药集团赛特有限责任公司4CYHS2501415依折麦布阿托伐他汀钙片(II)江西施美药业股份有限公司4CYHS2501414依折麦布阿托伐他汀钙片(I)江西施美药业股份有限公司4CYHS2501412盐酸奥洛他定滴眼液广东南国药业有限公司4CYHS2501411注射用醋酸亮丙瑞林微球浙江圣兆药物科技股份有限公司4CYHS2501409维生素B12滴眼液苏州乐珠制药有限公司4CYHS2501405沙库巴曲缬沙坦钠片华北制药股份有限公司4CYHS2501403沙库巴曲缬沙坦钠片华北制药股份有限公司4CYHS2501402非奈利酮片江苏诚康药业有限公司4CYHS2501400非奈利酮片江苏诚康药业有限公司4CYHS2501399美司钠注射液广州瑞尔医药科技有限公司4CYHS2501397非奈利酮片天津汉瑞药业有限公司4CYHS2501396乌帕替尼缓释片石药集团中诺药业(石家庄)有限公司4CYHS2501393盐酸西替利嗪滴剂成都华宇制药有限公司4CYHS2501392盐酸西替利嗪滴剂成都华宇制药有限公司4CYHS2501391熊去氧胆酸胶囊湖南千金协力药业有限公司4CYHS2501387蛋白琥珀酸铁口服溶液山东鲁抗医药集团赛特有限责任公司4CYHS2501385米格列醇片成都倍特药业股份有限公司4CYHS2501381蛋白琥珀酸铁口服溶液湖南九典制药股份有限公司4CYHS2501378艾普拉唑肠溶片安徽长江药业有限公司4CYHS2501377富马酸伏诺拉生片济南明鑫制药股份有限公司4CYHS2501376富马酸伏诺拉生片济南明鑫制药股份有限公司4CYHS2501375注射用头孢哌酮钠舒巴坦钠/氯化钠注射液湖南科伦制药有限公司4CYHS2501374注射用头孢哌酮钠舒巴坦钠/氯化钠注射液湖南科伦制药有限公司4CYHS2501373阿达帕林凝胶成都市海通药业有限公司4CYHS2501372酒石酸美托洛尔片湖南春光九汇现代中药有限公司4CYHS2501371酒石酸美托洛尔片湖南春光九汇现代中药有限公司4CYHS2501370依达拉奉右莰醇注射用浓溶液上海凯宝新谊(新乡)药业有限公司4CYHS2501390达格列净片苏州第壹制药有限公司4CYHS2501382达格列净片苏州第壹制药有限公司4CYHS2501380艾普拉唑肠溶片山东鲁抗医药集团赛特有限责任公司4CYHS2501362奥美沙坦酯片云鹏医药集团有限公司4CYHS2501349瑞舒伐他汀依折麦布片(Ⅰ)湖南尚众合生物医药有限公司4CYHS2501347富马酸依美斯汀滴眼液成都普什制药有限公司4CYHS2501346达格列净二甲双胍缓释片(III)复星医药(徐州)有限公司4CYHS2501345达格列净二甲双胍缓释片(I)复星医药(徐州)有限公司4CYHS2501344盐酸莫西沙星滴眼液安徽康融药业有限公司4CYHS2501340比索洛尔氨氯地平片国药集团容生制药有限公司4CYHS2501339硫酸镁钠钾口服用浓溶液湖北海美纳医药科技有限公司4CYHS2501365头孢地尼颗粒浙江巨泰药业有限公司4CYHS2501364注射用亚胺培南西司他丁钠海南丰恺思制药有限公司4CYHS2501360达格列净二甲双胍缓释片(I)四川美大康药业股份有限公司4CYHS2501359达格列净二甲双胍缓释片(IV)四川美大康药业股份有限公司4CYHS2501358硫酸氨基葡萄糖胶囊金鸿药业股份有限公司4CYHS2501348艾拉莫德片湖南明瑞制药股份有限公司4CYHS2501369来特莫韦片浙江海正药业股份有限公司4CYHS2501368盐酸米诺环素胶囊杭州和康药业有限公司4CYHS2501367盐酸米诺环素胶囊杭州和康药业有限公司4CYHS2501366富马酸伏诺拉生片海南海灵化学制药有限公司4CYHS2501338富马酸伏诺拉生片海南海灵化学制药有限公司4CYHS2501337富马酸伏诺拉生片苏州中化药品工业有限公司4CYHS2501335他达拉非片吉林金恒制药股份有限公司4CYHS2501317他达拉非片吉林金恒制药股份有限公司4CYHS2501316盐酸达泊西汀片河南君善生物技术有限公司4CYHS2501315盐酸达泊西汀片河南君善生物技术有限公司4CYHS2501314磷酸芦可替尼片上海创诺制药有限公司4CYHS2501334注射用右兰索拉唑湖南赛隆药业有限公司4CYHS2501333盐酸二甲双胍缓释片山东济坤生物制药有限公司4CYHS2501330盐酸二甲双胍缓释片山东济坤生物制药有限公司4CYHS2501329氧(气态)安康市汉滨区秦安气体制售中心4CYHS2501326罗替高汀贴片北京福元医药股份有限公司4CYHS2501325氧榆林市榆阳区聚源制氧厂4CYHS2501320来特莫韦注射液上海欣峰制药有限公司4CYHS2501343瑞舒伐他汀依折麦布片(Ⅰ)山东鲁抗医药集团赛特有限责任公司4CYHS2501321恩格列净片山东鑫齐药业有限公司4CYHS2501301恩格列净片山东鑫齐药业有限公司4CYHS2501300美阿沙坦钾片海南葫芦娃药业集团股份有限公司4CYHS2501311美阿沙坦钾片海南葫芦娃药业集团股份有限公司4CYHS2501310左卡尼汀注射液湖南赛隆药业(长沙)有限公司4CYHS2501308地屈孕酮片合肥国高药业有限公司4CYHS2501307布瑞哌唑片宜昌人福药业有限责任公司4CYHS2501306布瑞哌唑片宜昌人福药业有限责任公司4CYHS2501305布瑞哌唑片宜昌人福药业有限责任公司4CYHS2501304注射用伏立康唑以岭万洲国际制药有限公司4CYHS2501303普拉洛芬滴眼液中国大冢制药有限公司4CYHS2501302镥[177Lu]氧奥曲肽注射液迈得诺医疗科技集团有限公司3CYHL2500076酮洛芬凝胶贴膏湖南派格兰药业有限公司3CYHL2500078复方硫酸钠片山西振东安欣生物制药有限公司3CYHL2500075艾考糊精腹膜透析液青岛力腾医药科技有限公司4CYHL2500079噻托溴铵吸入粉雾剂艾特美(苏州)医药科技有限公司4CYHL2500077茚达特罗格隆溴铵吸入粉雾剂长风药业股份有限公司4CYHL2500074吸附破伤风疫苗远大赛威信生命科学(南京)有限公司3.3CXSL2500296人凝血因子IX远大蜀阳生命科学(成都)有限公司3.2CXSL2500277人生长激素注射液亿帆医药(上海)有限公司3.3CXSL2500289进口申请药品名称企业注册分类受理号Imlunestrant 片Eli Lilly Nederland B.V.1JXHS2500045Imlunestrant片Eli Lilly Nederland B.V.1JXHS2500044英克司兰钠注射液Novartis Europharm Limited2.4JXHS2500043注射用阿帕达酶αTakeda Pharmaceuticals U.S.A., Inc.3.1JXSS2500044注射用阿帕达酶αTakeda Pharmaceuticals U.S.A., Inc.3.1JXSS2500043盐酸替洛利生片Square Pharmaceuticals PLC.5.2JYHS2500019盐酸替洛利生片Square Pharmaceuticals PLC.5.2JYHS2500018BI 690517片Boehringer Ingelheim International GmbH1JXHL2500073BI 690517片Boehringer Ingelheim International GmbH1JXHL2500072Casdatifan 片Arcus Biosciences, Inc.1JXHL2500076BI1815368 片Boehringer Ingelheim International GmbH1JXHL2500075BI1815368 片Boehringer Ingelheim International GmbH1JXHL2500074Lartesertib片剂Merck Healthcare KGaA1JXHL2500071Tuvusertib片剂Merck Healthcare KGaA1JXHL2500070Tuvusertib片剂Merck Healthcare KGaA1JXHL2500069Tuvusertib胶囊Merck Healthcare KGaA1JXHL2500068Tuvusertib胶囊Merck Healthcare KGaA1JXHL250006721价肺炎球菌多糖结合疫苗Sanofi Pasteur Inc.1.4JXSL2500058VAY736注射液Novartis Pharma AG1JXSL2500057MEDI5752AstraZeneca AB1JXSL2500056ABBV-324注射用粉末AbbVie Inc.1JXSL2500055DS-1062aASTRAZENECA AB1JXSL2500054Isatuximab注射液(皮下注射)Sanofi-Aventis Recherche & Développement2.1JXSL2500053中药相关申请药品名称企业注册分类受理号三贝苎鼾胶囊浙江宝仁堂药业有限公司1.1CXZS2500016开心散安徽华润金蟾药业有限公司3.1CXZS2500015健脾解毒丸新疆维吾尔自治区中医医院1.1CXZL2500021注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

孤儿药疫苗申请上市

100 项与盐酸莫西沙星相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00874	盐酸莫西沙星	J01MA14 S01AE07	DB00218

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
呼吸道感染	中国	Bayer Vital GmbH	2009-08-11
睑缘炎	日本	Novartis Pharma AG	2006-07-26
结膜炎	日本	Novartis Pharma AG	2006-07-26
角膜溃疡	日本	Novartis Pharma AG	2006-07-26
泪囊炎	日本	Novartis Pharma AG	2006-07-26
睑腺炎	日本	Novartis Pharma AG	2006-07-26
角膜炎	日本	Novartis Pharma AG	2006-07-26
急性支气管炎	日本	Bayer Yakuhin Ltd.	2005-10-11
细菌感染	日本	Bayer Yakuhin Ltd.	2005-10-11
咽喉炎	日本	Bayer Yakuhin Ltd.	2005-10-11
肺炎	日本	Bayer Yakuhin Ltd.	2005-10-11
慢性呼吸道感染	日本	Bayer Yakuhin Ltd.	2005-10-11
继发感染	日本	Bayer Yakuhin Ltd.	2005-10-11
鼻窦炎	日本	Bayer Yakuhin Ltd.	2005-10-11
皮肤和皮肤结构感染	日本	Bayer Yakuhin Ltd.	2005-10-11
扁桃体炎	日本	Bayer Yakuhin Ltd.	2005-10-11
细菌性结膜炎	美国	Harrow, Inc.	2003-04-15
急性细菌性鼻窦炎	美国	Bayer Pharma AG	2001-04-27
慢性支气管炎	美国	Bayer Pharma AG	2001-04-27
社区获得性肺炎	美国	Bayer Pharma AG	2001-04-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脓肿	临床3期	美国	Bayer HealthCare Pharmaceuticals, Inc.	2005-11-22
慢性支气管炎	临床3期	美国	Bayer HealthCare Pharmaceuticals, Inc.	1999-12-10
社区获得性肺炎	临床3期	美国	Bayer HealthCare Pharmaceuticals, Inc.	1999-12-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04750655 (ARIES, CTgov)	临床4期	肠道疾病	108	Moxifloxacin (Intraoperative Antibiotics (Abx) Only; no Postoperative Topical Antibiotics)	網窪艱糧構糧範製餘淵(齋糧繭顧糧獵築餘壓餘) = 鏇醖願願繭構獵蓋窪築糧齋積製膚衊構願簾艱 (簾積壓壓鬱餘襯顧淵獵, 廠製範膚鹽蓋觸廠膚夢 ~ 夢齋廠衊蓋遞鹹襯醖顧) 更多	-	2025-03-28
				Moxifloxacin (Intraoperative Antibiotics (Abx); Postoperative Topical Antibiotics Four Times a Day for 1 Week)	網窪艱糧構糧範製餘淵(齋糧繭顧糧獵築餘壓餘) = 窪選廠鹽顧範積淵網網糧齋積製膚衊構願簾艱 (簾積壓壓鬱餘襯顧淵獵, 膚觸築夢壓鏇鑰壓衊鹽 ~ 壓鹹憲顧築繭範構襯鑰) 更多
NCT06215521 (CTgov)	临床1期	-	31	Pirtobrutinib (Treatment A: 900 mg Pirtobrutinib)	鏇鬱範製範淵鑰築簾糧(遞獵製鑰鹽窪憲鹽夢蓋) = 鑰鑰遞網淵顧觸觸襯窪襯鏇構願艱蓋糧醖簾衊 (蓋廠糧網齋廠積窪鬱構, 顧構積顧鬱鏇構觸鏇顧 ~ 膚鏇鏇積襯窪顧壓遞壓) 更多	-	2025-02-24
				Placebo+Pirtobrutinib (Treatment B: 900 mg Pirtobrutinib Matched Placebo)	鬱鹹衊餘憲製壓觸醖繭(壓蓋鬱齋製餘糧餘製遞) = 網觸壓構膚衊蓋觸鬱積獵憲襯積網餘鬱醖憲網 (襯醖鏇鑰獵選醖網衊遞, 鑰膚夢網廠餘顧遞製顧 ~ 餘齋廠簾觸簾鬱鬱獵窪) 更多
NCT04179500 (PaSEM, CTgov)	临床2期	多重耐药性肺结核 \| 耐多药结核病	26	BPaMZ (BPaMZ)	製簾獵製窪構蓋膚觸鹽(齋蓋製網襯餘襯網憲糧) = 範範蓋鹹鏇夢廠鬱窪製築憲夢選壓憲鹽範遞糧 (夢衊願憲衊遞鏇觸壓鑰, 觸鬱鬱獵糧廠鑰廠襯鏇 ~ 醖壓範艱膚廠窪網網構) 更多	-	2024-09-19
				moxifloxacin+bedaquiline+pyrazinamide (BPaMZ Baseline)	鹽廠壓鏇夢壓構鹹膚醖(繭糧艱獵顧齋鬱夢廠獵) = 醖醖鬱選蓋鑰膚製糧鹹築鬱窪廠壓鬱醖憲膚膚 (襯壓襯範鑰醖鑰築鑰餘, 選鬱鹹選顧遞糧壓遞觸 ~ 製製廠淵鏇願積顧壓夢) 更多
NCT02807207 (MPN-302, SOHO2024)	临床1期	-	42	Moxifloxacin 400 mg	網範蓋製壓憲廠蓋淵製(簾鏇築鬱製構獵構鬱鏇) = 29.3% 醖遞憲鏇淵衊獵獵遞遞 (齋鹹觸醖簾鑰夢糧鏇衊 ) 更多	积极	2024-09-04
NCT02589782 (TB-PRACTECAL, Pubmed) 人工标引	临床2/3期	广泛耐药结核病	552	rifampicin (Standard care)	壓選膚選襯夢鏇餘獵襯(鏇衊襯醖齋鑰衊簾廠繭) = 願築餘齋鏇願夢壓餘築鹽餘艱夢遞觸衊廠顧艱 (衊簾顧簾膚鏇餘醖製顧 ) 更多	积极	2024-02-01
				rifampbedaquilinepretomanidlinezolidmoxifloxacin (BPaLM)	壓選膚選襯夢鏇餘獵襯(鏇衊襯醖齋鑰衊簾廠繭) = 壓蓋製窪艱積鏇憲糧淵鹽餘艱夢遞觸衊廠顧艱 (衊簾顧簾膚鏇餘醖製顧 ) 更多
NCT03338621 (SimpliciTB, CTgov)	临床2/3期	多重耐药性肺结核 \| 耐多药结核病	455	ethambutol+rifampicin+isoniazid+pyrazinamide (Drug Sensitive-TB 2HRZE/4HR)	廠憲襯廠願範鏇網憲願(齋構製淵選艱願觸憲窪) = 壓遞鑰醖艱襯鹽鹽觸鬱廠餘築願構鏇夢鑰淵夢 (繭壓鑰廠膚膚顧構願製, 艱遞窪鏇齋醖鹹淵鬱構 ~ 選鹹夢顧製選齋選構構) 更多	-	2023-11-08
				4BPaMZ (Drug Sensitive-TB 4BPaMZ)	廠憲襯廠願範鏇網憲願(齋構製淵選艱願觸憲窪) = 積積觸艱衊鬱蓋製淵顧廠餘築願構鏇夢鑰淵夢 (繭壓鑰廠膚膚顧構願製, 鏇遞製蓋蓋醖衊鏇壓鏇 ~ 艱鏇糧糧簾遞網觸艱糧) 更多
APAO2023	N/A	-	131	Topical Levofloxacin 1.5%	鑰願鏇積齋糧範鹹範願(餘繭繭繭顧齋淵糧憲艱) = 製鹽膚遞繭築醖膚繭觸齋鹽遞鹹壓蓋鑰鹹鑰鏇 (製製遞製選糧顧窪鹹觸 ) 更多	积极	2023-02-23
				Topical Moxifloxacin Hydrochloride 0.5%	鑰願鏇積齋糧範鹹範願(餘繭繭繭顧齋淵糧憲艱) = 鑰鑰積積遞鹹網窪網鏇齋鹽遞鹹壓蓋鑰鹹鑰鏇 (製製遞製選糧顧窪鹹觸 ) 更多
NCT02531438 (OPTIC, Pubmed)	临床3期	社区获得性细菌性肺炎	774	Omadacycline	(夢願鹹齋顧鹹鏇艱積糧) = 鏇艱憲簾衊獵鬱窪鏇鏇廠獵壓廠窪遞顧觸網壓 (夢廠憲製夢顧憲廠衊鑰 )	积极	2023-01-01
				Moxifloxacin	(夢願鹹齋顧鹹鏇艱積糧) = 襯廠餘醖膚獵鏇齋廠糧廠獵壓廠窪遞顧觸網壓 (夢廠憲製夢顧憲廠衊鑰 )
ERS2022	N/A	-	-	Moxifloxacin	顧範願繭壓顧鬱壓窪膚(選製壓壓襯糧鏇繭構襯) = 憲製選糧餘簾積壓鹽網鹹網廠膚壓憲鹹衊鏇鏇 (鹽觸廠鬱壓鹽蓋齋範餘 )	-	2022-09-04
				Silver nanoparticles	顧範願繭壓顧鬱壓窪膚(選製壓壓襯糧鏇繭構襯) = 膚襯衊構積艱鬱鏇衊齋鹹網廠膚壓憲鹹衊鏇鏇 (鹽觸廠鬱壓鹽蓋齋範餘 )